» Articles » PMID: 28181828

Synthesis of Sericin-based Conjugates by Click Chemistry: Enhancement of Sunitinib Bioavailability and Cell Membrane Permeation

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2017 Feb 10
PMID 28181828
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Sericin is a natural protein that has been used in biomedical and pharmaceutical fields as raw material for polypeptide-based drug delivery systems (DDSs). In this paper, it has been employed as pharmaceutical biopolymer for the production of sunitinib-polypeptide conjugate. The synthesis has been carried out by simple click reaction in water, using the redox couple l-ascorbic acid/hydrogen peroxide as a free radical grafting initiator. The bioconjugate molecular weight (50 kDa < Mw < 75 kDa) was obtained by SDS-PAGE, while the spectroscopic characteristics have been studied in order to reveal the presence of grafted sunitinib. In both FT-IR and UV/Vis spectra, signals corresponding to sunitinib functional groups have been identified. Since sunitinib is an anticancer drug characterized by low bioavailability and low permeability, the bioconjugation aimed at their enhancement. In vitro studies demonstrated that bioavailability has been increased to almost 74%, compared with commercial formulation. Also cell membrane permeability has been augmented in in vitro tests, in which membrane models have been used to determine the lipid membrane/physiological fluid partition coefficient (Kp). The log(Kp) value of the bioconjugate was increased to over 4. This effect resulted in a three-fold decrease of IC value against MCF-7 cells.

Citing Articles

Exploring Protein-Based Carriers in Drug Delivery: A Review.

Ferraro C, Dattilo M, Patitucci F, Prete S, Scopelliti G, Parisi O Pharmaceutics. 2024; 16(9).

PMID: 39339208 PMC: 11435266. DOI: 10.3390/pharmaceutics16091172.


A Bioengineering Approach for the Development of Fibroblast Growth Factor-7-Functionalized Sericin Biomaterial Applicable for the Cultivation of Keratinocytes.

Lian A, Yamaji Y, Kajiwara K, Takaki K, Mori H, Liew M Int J Mol Sci. 2022; 23(17).

PMID: 36077351 PMC: 9456417. DOI: 10.3390/ijms23179953.


Molecularly Imprinted Polymers (MIPs) as Theranostic Systems for Sunitinib Controlled Release and Self-Monitoring in Cancer Therapy.

Parisi O, Ruffo M, Malivindi R, Vattimo A, Pezzi V, Puoci F Pharmaceutics. 2020; 12(1).

PMID: 31947815 PMC: 7022407. DOI: 10.3390/pharmaceutics12010041.

References
1.
Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L . Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Drug Des Devel Ther. 2014; 8:2061-7. PMC: 4219427. DOI: 10.2147/DDDT.S63840. View

2.
Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U . Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011; 50(9):551-603. DOI: 10.2165/11593320-000000000-00000. View

3.
Zhao L, Liu C, Sun Y, Ban L . A rapid and simplified method for protein silver staining in polyacrylamide gels. Electrophoresis. 2012; 33(14):2143-4. DOI: 10.1002/elps.201200107. View

4.
Bouayed J, Hoffmann L, Bohn T . Total phenolics, flavonoids, anthocyanins and antioxidant activity following simulated gastro-intestinal digestion and dialysis of apple varieties: Bioaccessibility and potential uptake. Food Chem. 2014; 128(1):14-21. DOI: 10.1016/j.foodchem.2011.02.052. View

5.
Zhang Y, Ma Y, Xia Y, Shen W, Mao J, Xue R . Silk sericin-insulin bioconjugates: synthesis, characterization and biological activity. J Control Release. 2006; 115(3):307-15. DOI: 10.1016/j.jconrel.2006.08.019. View